Berberine Emerges as Multi-Target Drug Candidate for Heart-Kidney-Metabolic Syndrome
Reverse network pharmacology pinpoints berberine as a promising treatment for CKM syndrome, validated in a novel mouse model combining metabolic and cardiac stress.
Summary
Cardiovascular-kidney metabolic syndrome (CKM) links obesity, diabetes, hypertension, and chronic kidney disease into a devastating multi-organ condition with few proven treatments. Researchers used reverse network pharmacology to mine disease gene databases, identify 183 shared targets across seven CKM-related diseases, and screen a natural product library for candidate drugs. This approach flagged berberine (BBR), a plant alkaloid, as a top candidate. To validate findings, researchers created a novel CKM mouse model using a high-fat diet plus L-NAME (an NOS inhibitor) for 12 weeks—producing metabolic dysfunction, cardiac diastolic dysfunction, and renal fibrosis simultaneously. Four weeks of BBR treatment improved all three disease domains by modulating lipid metabolism, glucose metabolism, and fibrosis-related pathways, suggesting berberine could become an affordable multi-target therapy for CKM.
Detailed Summary
Cardiovascular-kidney metabolic syndrome (CKM) is a newly defined syndrome by the American Heart Association encompassing obesity, diabetes, hypertension, atherosclerosis, and chronic kidney disease (CKD) as interconnected, mutually reinforcing conditions. Despite growing prevalence, existing therapies—including SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists—only partially address the syndrome's full spectrum, particularly its earliest metabolic stages. There is urgent demand for accessible, affordable, multi-target treatments.
This study employed reverse network pharmacology to systematically identify candidate drugs for CKM. Researchers queried GeneCards, OMIM, and DisGeNET using seven disease keywords aligned with AHA's CKM staging (hyperlipidemia, diabetes, obesity, hypertension, atherosclerosis, coronary heart disease, and CKD). After filtering by relevance score (top 25% in GeneCards), 183 common targets were identified across all seven conditions. These were analyzed via STRING protein-protein interaction (PPI) network construction (confidence >0.9), Cytoscape visualization, and GO/KEGG pathway enrichment. Core hub targets were identified and used to query a natural product library through reverse pharmacology, yielding berberine (BBR) as a top candidate compound with predicted activity across multiple CKM-relevant pathways.
A key contribution of this work is the development and validation of a novel CKM animal model. Male C57BL/6J mice were fed a high-fat diet combined with L-NAME (an eNOS inhibitor) for 12 weeks. This 'two-hit' protocol—previously established for heart failure with preserved ejection fraction (HFpEF)—reproducibly induced metabolic disorders (dyslipidemia, insulin resistance), cardiac diastolic dysfunction, and renal structural damage (fibrosis, glomerulosclerosis) simultaneously, making it a more comprehensive CKM model than prior single-hit approaches. The model also showed documented responsiveness to known CKM-targeting drugs like SGLT2 inhibitors, reinforcing its validity.
Following model establishment, mice received four weeks of BBR treatment. BBR significantly improved multiple metabolic parameters, restored cardiac diastolic function (assessed echocardiographically), and reduced renal fibrosis and damage markers. Mechanistic validation via RT-qPCR and Western blotting confirmed BBR's activity on lipid metabolism, glucose homeostasis, and fibrosis-related signaling pathways—consistent with the network pharmacology predictions. Pathological analyses corroborated structural improvements in both heart and kidney tissue.
These findings position berberine—a low-cost, widely available alkaloid derived from plants such as Berberis—as a multi-target therapeutic candidate for CKM. The study also establishes the HFD + L-NAME 'two-hit' model as a practical and translationally relevant platform for CKM research and drug screening. Limitations include the restriction to male mice, the absence of direct comparison with established CKM drugs, and the computational nature of target identification requiring further mechanistic dissection. Human clinical validation remains a necessary next step.
Key Findings
- 183 shared molecular targets identified across seven CKM-related diseases using multi-database network pharmacology.
- Reverse pharmacology screening of a natural product library identified berberine (BBR) as a top multi-target CKM drug candidate.
- HFD + L-NAME 'two-hit' mouse model simultaneously reproduces metabolic dysfunction, cardiac diastolic dysfunction, and renal fibrosis.
- BBR treatment improved lipid and glucose metabolism, cardiac diastolic function, and renal fibrosis in CKM mice over 4 weeks.
- RT-qPCR and Western blotting confirmed BBR modulates lipid metabolism, glucose metabolism, and fibrosis-related pathways in vivo.
Methodology
Reverse network pharmacology was used to screen 183 common CKM targets from GeneCards, OMIM, and DisGeNET, followed by PPI network analysis and KEGG/GO enrichment to identify berberine. A 'two-hit' CKM mouse model (HFD + L-NAME, 12 weeks, male C57BL/6J) was constructed and treated with BBR for 4 weeks, with outcomes assessed via echocardiography, metabolic profiling, pathological staining, RT-qPCR, and Western blotting.
Study Limitations
The study used only male mice, limiting generalizability across sexes. No head-to-head comparison with established CKM therapies (e.g., SGLT2 inhibitors or GLP-1 agonists) was performed. Network pharmacology target predictions are computational and require further mechanistic and clinical validation before therapeutic conclusions can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.